Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced it will report its financial results for the first quarter of 2023 on May 3, 2023, after market close. A conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET, which will be accessible via the company’s website. The company focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases, including cancer and autoimmune disorders. Their proprietary platform aims to unlock the full potential of the immune system, enhancing diagnosis and treatment precision. The company emphasizes its commitment to developing individualized immune-driven clinical products.

Positive

• Planned Q1 2023 financial results announcement, indicating ongoing business operations.
• Focus on innovative immune-driven clinical products tailored to individual patients, suggesting potential for growth and development.

Negative

• None.

SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies report its Q1 2023 financial results?

Adaptive Biotechnologies will report its Q1 2023 financial results on May 3, 2023, after market close.

What time is the conference call for Q1 2023 results?

The conference call for Q1 2023 results will begin at 1:30 p.m. PT / 4:30 p.m. ET.

Where can I listen to the Adaptive Biotechnologies Q1 2023 financial results webcast?

The webcast can be accessed on the 'Investors' section of the Adaptive Biotechnologies website.

What is the focus area of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on harnessing the adaptive immune system for the diagnosis and treatment of diseases.